Although the interest in developing leukemia therapies by targeting H3K9 methyltransferases is increasing [41], the role of Suv39h1 and its associated H3K9me3 modification in MLL-r AML remains unclear. This evidence concerns the gene SUV39H1 and acute myeloid leukemia.